Eureka Therapeutics, Inc., an Emeryville, CA-based clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, completed a $60m Series D financing round.
The round was led by Acorn Pacific Ventures with participation from GP Capital and all existing major investors.
The company intends to use the proceeds to advance its lead candidate, ET190L1-ARTEMIS™ T cells in relapsed and refractory CD19+ Non-Hodgkin Lymphoma, as well as to accelerate its pipeline of innovative immunotherapies against other hematological and solid tumors.
Led by Cheng Liu, PhD, President and Chief Executive Officer, Eureka is a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing T cell therapies for hematological malignancies and solid tumors. The company’s core technology centers around its proprietary ARTEMIS™ T cell receptor platform and proprietary E-ALPHA® phage display library for the discovery and engineering of human antibodies against intracellular targets via the MHC class I complex. The company is developing a pipeline of novel cancer therapeutics targeting intracellular oncogenes as well as cell-surface antigens.
In November 2017, the U.S. Food and Drug Administration (FDA) approved Eureka’s investigational new drug (IND) application and authorized the company to commence a Phase I clinical trial for ET190L1-ARTEMIS™ T cells in Relapsed and Refractory CD19+ Non-Hodgkin Lymphoma (NHL). Eureka expects to enroll the first patient in this trial at Duke University in the first quarter of 2018.